Current Status and Advances in Radiotherapy for Biliary Tract Cancers
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v7i2.5325
Abstract
Biliary tract cancers (BTCs) are insidious and carry extremely poor prognosis, with most patients unresectable at diagnosis. Radiotherapy is an important local treatment, but conventional methods cannot balance target dose and normal tissue protection due to complex anatomy adjacent to radiosensitive organs. In recent years, precise radiotherapy including IMRT, VMAT, IGRT, MRgRT and particle therapy has greatly improved accuracy. BED-based dose escalation, SIB and functional imaging-guided optimization further balance efficacy and safety. This review summarizes precise radiotherapy techniques, dosimetric optimization, clinical applications, current challenges and future directions.
Keywords
biliary tract cancers; precise radiotherapy; dosimetric optimization; clinical application
Full Text
PDF - Viewed/Downloaded: 4 TimesReferences
[1] Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 17. England2020. p. 557–88.
[2] Yang SQ, Feng H, Tian Y, Zou RQ, Dai YS, Hu HJ, et al. Unraveling early recurrence of risk factors in Gallbladder cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2024;50(7):108372.
[3] Benson AB, 3rd, D'Angelica MI, Abrams T, Ahmed A, Akce M, Anaya DA, et al. Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(9):403–18.
[4] Yankey H, Ruth KJ, Dotan E, Reddy S, Meyer JE. Survival and Toxicity in Patients With Unresectable or Inoperable Biliary Tract Cancers With Ablative Radiation Therapy Versus Nonablative Chemoradiation. Adv Radiat Oncol. 9. United States2024. p. 101412.
[5] Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 33. United States2015. p. 2617–22.
[6] Jia AY, Wu JX, Zhao YT, Li YX, Wang Z, Rong WQ, et al. Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma. J Gastrointest Oncol. 6. China2015. p. 126–33.
[7] Vogel A, Bridgewater J, Edeline J, Kelley RK, Klumpen HJ, Malka D, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–40.
[8] Engineer R, Goel M, Chopra S, Patil P, Purandare N, Rangarajan V, et al. Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Gallbladder Cancers: A New Paradigm. Ann Surg Oncol. 23. United States2016. p. 3009–15.
[9] Kumar D, Samanta J, Mandavdhare H, Irrinki S, Gupta P, Gupta P, et al. A prospective pilot study to evaluate the impact of palliative radiotherapy in upfront inoperable/chemo unfit patients with extrahepatic biliary tract tumors. Reports of Practical Oncology and Radiotherapy. 2026;31(1):34–41.
[10] Song J, Kang X, Di Y, Ren G, Wang Y. Associations between external beam radiotherapy and overall survival in patients with gallbladder cancer: A population-based study. Front Public Health. 2022;10:1012142.
[2] Yang SQ, Feng H, Tian Y, Zou RQ, Dai YS, Hu HJ, et al. Unraveling early recurrence of risk factors in Gallbladder cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2024;50(7):108372.
[3] Benson AB, 3rd, D'Angelica MI, Abrams T, Ahmed A, Akce M, Anaya DA, et al. Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(9):403–18.
[4] Yankey H, Ruth KJ, Dotan E, Reddy S, Meyer JE. Survival and Toxicity in Patients With Unresectable or Inoperable Biliary Tract Cancers With Ablative Radiation Therapy Versus Nonablative Chemoradiation. Adv Radiat Oncol. 9. United States2024. p. 101412.
[5] Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 33. United States2015. p. 2617–22.
[6] Jia AY, Wu JX, Zhao YT, Li YX, Wang Z, Rong WQ, et al. Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma. J Gastrointest Oncol. 6. China2015. p. 126–33.
[7] Vogel A, Bridgewater J, Edeline J, Kelley RK, Klumpen HJ, Malka D, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127–40.
[8] Engineer R, Goel M, Chopra S, Patil P, Purandare N, Rangarajan V, et al. Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Gallbladder Cancers: A New Paradigm. Ann Surg Oncol. 23. United States2016. p. 3009–15.
[9] Kumar D, Samanta J, Mandavdhare H, Irrinki S, Gupta P, Gupta P, et al. A prospective pilot study to evaluate the impact of palliative radiotherapy in upfront inoperable/chemo unfit patients with extrahepatic biliary tract tumors. Reports of Practical Oncology and Radiotherapy. 2026;31(1):34–41.
[10] Song J, Kang X, Di Y, Ren G, Wang Y. Associations between external beam radiotherapy and overall survival in patients with gallbladder cancer: A population-based study. Front Public Health. 2022;10:1012142.
Copyright © 2026 Yu Li, Xiaocai Tian
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License